IRLA

SEC source: 0001779453-19-000003 · primary_doc.xml · nonDerivative · entry 3

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner

Boeding Chad · CIK 0001779451 · Managing Member of IA

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust

Disclosed balance after: 2,832,926

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000007 · primary_doc.xml · nonDerivative · entry 4

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,847,575

F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: Beneficially owned directly by Mr. Boeding.

SEC source: 0001779453-19-000007 · primary_doc.xml · nonDerivative · entry 3

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust

Disclosed balance after: 2,845,940

F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000003 · primary_doc.xml · nonDerivative · entry 2

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner

Boeding Chad · CIK 0001779451 · Managing Member of IA

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,832,506

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: Beneficially owned directly by Mr. Boeding.

SEC source: 0001779453-19-000003 · primary_doc.xml · nonDerivative · entry 1

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner

Boeding Chad · CIK 0001779451 · Managing Member of IA

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee for Boeding Family Trust

Disclosed balance after: 2,830,196

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000007 · primary_doc.xml · nonDerivative · entry 2

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,845,520

F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: Beneficially owned directly by Mr. Boeding.

SEC source: 0001779453-19-000007 · primary_doc.xml · nonDerivative · entry 1

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee for Boeding Family Trust

Disclosed balance after: 2,843,210

F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779451-19-000001 · primary_doc.xml · nonDerivative · entry 2

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner

Boeding Chad · CIK 0001779451 · Managing Member of IA

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust

Disclosed balance after: 2,829,596

F1 · ownership.direct: 1 The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000006 · primary_doc.xml · nonDerivative · entry 2

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust

Disclosed balance after: 2,842,610

F2 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/19/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779451-19-000001 · primary_doc.xml · nonDerivative · entry 1

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner

Boeding Chad · CIK 0001779451 · Managing Member of IA

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust

Disclosed balance after: 2,827,496

F1 · ownership.direct: 1 The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000006 · primary_doc.xml · nonDerivative · entry 1

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust

Disclosed balance after: 2,840,510

F2 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/19/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-19-046227 · doc4.xml · derivative · entry 1

Gafric Kristen · CIK 0001770840 · SVP, Legal & Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires not disclosed

F1 · derivative.exercise_date: 1/48th of the total number of shares subject to this option will vest and become exercisable on each monthly anniversary of the vesting start date, beginning February 1, 2019, and for so long as the Reporting Person remains a Service Provider (as defined in the Issuer's Stock Plan).

F1 · derivative.expiration_date: 1/48th of the total number of shares subject to this option will vest and become exercisable on each monthly anniversary of the vesting start date, beginning February 1, 2019, and for so long as the Reporting Person remains a Service Provider (as defined in the Issuer's Stock Plan).

SEC source: 0001209191-19-029477 · doc4.xml · derivative · entry 8

LAMOND PIERRE · CIK 0001190683 · 10% owner

Lamond Christine · CIK 0001775830 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019

Disclosed balance after: 0

Underlying: Common Stock · 462,028 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F4 · ownership.nature: Pierre R. Lamond is the trustee of the Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019, and has sole voting and dispositive power with respect to the shares held of record by the Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019.

SEC source: 0001209191-19-029477 · doc4.xml · derivative · entry 7

LAMOND PIERRE · CIK 0001190683 · 10% owner

Lamond Christine · CIK 0001775830 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019

Disclosed balance after: 0

Underlying: Common Stock · 462,027 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.nature: Christine E. Lamond is the trustee of the Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019, and has sole voting and dispositive power with respect to the shares held of record by the Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019.

SEC source: 0001209191-19-029477 · doc4.xml · derivative · entry 6

LAMOND PIERRE · CIK 0001190683 · 10% owner

Lamond Christine · CIK 0001775830 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pierre R. and Christine E. Lamond Trust 11-22-85

Disclosed balance after: 0

Underlying: Common Stock · 961,510 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F5 · ownership.nature: Pierre R. Lamond is the trustee of the Pierre R. and Christine E. Lamond Trust 11-22-85, and has sole voting and dispositive power with respect to the shares held of record by the Pierre R. and Christine E. Lamond Trust 11-22-85.

SEC source: 0001209191-19-029477 · doc4.xml · derivative · entry 5

LAMOND PIERRE · CIK 0001190683 · 10% owner

Lamond Christine · CIK 0001775830 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019

Disclosed balance after: 0

Underlying: Common Stock · 500,482 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F4 · ownership.nature: Pierre R. Lamond is the trustee of the Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019, and has sole voting and dispositive power with respect to the shares held of record by the Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019.

SEC source: 0001209191-19-029477 · doc4.xml · derivative · entry 4

LAMOND PIERRE · CIK 0001190683 · 10% owner

Lamond Christine · CIK 0001775830 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019

Disclosed balance after: 0

Underlying: Common Stock · 500,483 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.nature: Christine E. Lamond is the trustee of the Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019, and has sole voting and dispositive power with respect to the shares held of record by the Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019.

SEC source: 0001209191-19-029477 · doc4.xml · nonDerivative · entry 3

LAMOND PIERRE · CIK 0001190683 · 10% owner

Lamond Christine · CIK 0001775830 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pierre R. and Christine E. Lamond Trust 11-22-85

Disclosed balance after: 961,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.

F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F5 · ownership.nature: Pierre R. Lamond is the trustee of the Pierre R. and Christine E. Lamond Trust 11-22-85, and has sole voting and dispositive power with respect to the shares held of record by the Pierre R. and Christine E. Lamond Trust 11-22-85.

SEC source: 0001209191-19-029477 · doc4.xml · nonDerivative · entry 2

LAMOND PIERRE · CIK 0001190683 · 10% owner

Lamond Christine · CIK 0001775830 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019

Disclosed balance after: 962,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.

F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F4 · ownership.nature: Pierre R. Lamond is the trustee of the Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019, and has sole voting and dispositive power with respect to the shares held of record by the Pierre R. Lamond 2019 Annuity Trust A dated March 4, 2019.

SEC source: 0001209191-19-029477 · doc4.xml · nonDerivative · entry 1

LAMOND PIERRE · CIK 0001190683 · 10% owner

Lamond Christine · CIK 0001775830 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019

Disclosed balance after: 962,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.

F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.nature: Christine E. Lamond is the trustee of the Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019, and has sole voting and dispositive power with respect to the shares held of record by the Christine E. Lamond 2019 Annuity Trust A dated March 4, 2019.

SEC source: 0001209191-19-029480 · doc4.xml · derivative · entry 3

Takeda Ventures, Inc. · CIK 0001771657 · 10% owner

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner

Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 319,731 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

SEC source: 0001209191-19-029480 · doc4.xml · derivative · entry 2

Takeda Ventures, Inc. · CIK 0001771657 · 10% owner

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner

Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,360,071 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

SEC source: 0001209191-19-029480 · doc4.xml · nonDerivative · entry 1

Takeda Ventures, Inc. · CIK 0001771657 · 10% owner

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner

Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,679,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.

F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

SEC source: 0001209191-19-029476 · doc4.xml · derivative · entry 5

Lamond David · CIK 0001770790 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Blue Devil Trust dated 12/03/2010

Disclosed balance after: 0

Underlying: Common Stock · 924,056 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.nature: Mr. Lamond is the trustee of the Blue Devil Trust dated 12/03/2010, and holds sole voting and dispositive power with respect to the shares held of record by Blue Devil Trust dated 12/03/2010.

SEC source: 0001209191-19-029476 · doc4.xml · derivative · entry 4

Lamond David · CIK 0001770790 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 301,829 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

SEC source: 0001209191-19-029476 · doc4.xml · derivative · entry 3

Lamond David · CIK 0001770790 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Blue Devil Trust dated 12/03/2010

Disclosed balance after: 0

Underlying: Common Stock · 699,280 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.nature: Mr. Lamond is the trustee of the Blue Devil Trust dated 12/03/2010, and holds sole voting and dispositive power with respect to the shares held of record by Blue Devil Trust dated 12/03/2010.

SEC source: 0001209191-19-029476 · doc4.xml · nonDerivative · entry 2

Lamond David · CIK 0001770790 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 301,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

SEC source: 0001209191-19-029476 · doc4.xml · nonDerivative · entry 1

Lamond David · CIK 0001770790 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Blue Devil Trust dated 12/03/2010

Disclosed balance after: 1,623,336

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.

F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · ownership.nature: Mr. Lamond is the trustee of the Blue Devil Trust dated 12/03/2010, and holds sole voting and dispositive power with respect to the shares held of record by Blue Devil Trust dated 12/03/2010.

SEC source: 0001209191-20-018558 · doc4.xml · nonDerivative · entry 1

YOUNG KEVIN · CIK 0001303643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

SEC source: 0001209191-20-018550 · doc4.xml · nonDerivative · entry 1

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Una S. Ryan Revocable Trust

Disclosed balance after: 2,875

F1 · ownership.nature: Shares reported herein are held of record by the Una S. Ryan Revocable Trust. Ms. Ryan is one of the trustees of the Una S. Ryan Revocable Trust, and has shared voting and dispositive power with respect to the shares held of record by the Una S. Ryan Revocable Trust.

SEC source: 0001209191-20-018537 · doc4.xml · nonDerivative · entry 1

McLoughlin Margaret · CIK 0001770823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550

SEC source: 0000078003-19-000027 · primary_doc.xml · derivative · entry 7

PFIZER INC · CIK 0000078003 · 10% owner

Pfizer Ventures (US) LLC · CIK 0001776087 · 10% owner

Pfizer Strategic Investment Holdings LLC · CIK 0001776115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 624,205 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.

SEC source: 0000078003-19-000027 · primary_doc.xml · derivative · entry 6

PFIZER INC · CIK 0000078003 · 10% owner

Pfizer Ventures (US) LLC · CIK 0001776087 · 10% owner

Pfizer Strategic Investment Holdings LLC · CIK 0001776115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 215,697 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.

SEC source: 0000078003-19-000027 · primary_doc.xml · derivative · entry 5

PFIZER INC · CIK 0000078003 · 10% owner

Pfizer Ventures (US) LLC · CIK 0001776087 · 10% owner

Pfizer Strategic Investment Holdings LLC · CIK 0001776115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,360,071 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.

SEC source: 0000078003-19-000027 · primary_doc.xml · nonDerivative · entry 4

PFIZER INC · CIK 0000078003 · 10% owner

Pfizer Ventures (US) LLC · CIK 0001776087 · 10% owner

Pfizer Strategic Investment Holdings LLC · CIK 0001776115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,249,973

F3 · price: PVUS purchased 50,000 additional shares of common stock in the Issuer's initial public offering for consideration of $17.00 per share.

F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.

SEC source: 0000078003-19-000027 · primary_doc.xml · nonDerivative · entry 3

PFIZER INC · CIK 0000078003 · 10% owner

Pfizer Ventures (US) LLC · CIK 0001776087 · 10% owner

Pfizer Strategic Investment Holdings LLC · CIK 0001776115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,199,973

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.

SEC source: 0000078003-19-000027 · primary_doc.xml · nonDerivative · entry 2

PFIZER INC · CIK 0000078003 · 10% owner

Pfizer Ventures (US) LLC · CIK 0001776087 · 10% owner

Pfizer Strategic Investment Holdings LLC · CIK 0001776115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,575,768

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.

SEC source: 0000078003-19-000027 · primary_doc.xml · nonDerivative · entry 1

PFIZER INC · CIK 0000078003 · 10% owner

Pfizer Ventures (US) LLC · CIK 0001776087 · 10% owner

Pfizer Strategic Investment Holdings LLC · CIK 0001776115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,360,071

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.

SEC source: 0001779453-19-000002 · primary_doc.xml · nonDerivative · entry 3

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner

Boeding Chad · CIK 0001779451 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as custodian for minor child

Disclosed balance after: 2,826,796

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 3 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000002 · primary_doc.xml · nonDerivative · entry 2

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner

Boeding Chad · CIK 0001779451 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust

Disclosed balance after: 2,826,716

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 3 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000002 · primary_doc.xml · nonDerivative · entry 1

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner

Boeding Chad · CIK 0001779451 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,822,546

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 3 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: Beneficially owned directly by Mr. Boeding.

SEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 3

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as custodian for minor child

Disclosed balance after: 2,839,810

F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 2

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust

Disclosed balance after: 2,839,730

F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 1

EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne

Boeding Chad · CIK 0001779451 · Managing Member of Managing Me

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,835,560

F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.

F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: Beneficially owned directly by Mr. Boeding.

SEC source: 0001209191-19-028537 · doc4.xml · derivative · entry 1

McLoughlin Margaret · CIK 0001770823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,911

Underlying: Common Stock · 91,911 shares

Expires 2029-05-07

F1 · derivative.exercise_date: The option will vest as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022.